Beyond Air 3Q 2026: Revenue $2.32M, EPS ($3.76) — 10-Q Summary

Beyond Air reported 3Q 2026 revenue of $2.32M, up 28% YoY, with a gross profit of $197K, reversing a prior-year loss. Net loss narrowed slightly. R&D expenses fell to $1.6M. LungFit GO received FDA Breakthrough Device Designation. The company expects to close the NeuroNOS divestiture in December 2026.

Original reporting
Published Nov 12, 2026, 2:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 2:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Beyond Air 3Q 2026: Revenue $2.32M, EPS ($3.76) — 10-Q Summary — source image
Decision brief

The 30-second read

$XAIRNeutralLow
01

Why it matters

The earnings beat on revenue and loss narrowing may provide a short‑term catalyst for the stock, though the absolute figures remain small.

02

Market read

Micro‑cap earnings release with modest improvements; limited broader market impact.

03

What to watch

The FDA Breakthrough Device Designation for LungFit GO could drive future upside not reflected in the current numbers.

Relevance 6/10Novelty 6/10Timing: after‑hours release

Background

Beyond Air, Inc. (NASDAQ: XAIR) filed its Form 10‑Q for Q3 2026, showing a 28% YoY revenue increase and a narrowed net loss.

Company-level read

Ticker impact

$XAIRNeutralMedium confidence
Context

Beyond Air reported Q3 2026 revenue of $2.32M and a narrowed net loss, marking the first public disclosure of its quarterly results.

Expected impact

potential slight upside as the market prices in the loss narrowing

Evidence & confidence

The company is a micro‑cap; the numbers are modest, but the improvement in gross profit and loss may attract short‑term buying.

Market effects

Limited impact on the broader med‑tech sector; signals incremental progress for lung‑fit devices.

Primarily U.S. micro‑cap investors; no broader regional effect.

Low global relevance.

Counterpoint

Investors may view the modest revenue and continued losses as a sign of ongoing cash‑burn, suggesting caution.

Key entities

  • Beyond Air, Inc.

    Medical device company focused on lung‑fit technologies.

Related articles

$XAIRLow

Beyond Air Reports Financial Results and Provides Corporate Update

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026 Record quarterly revenue of $2.3 million, representing approximately 28% year-over-year growth, reflecting continued adoption of first-generation LungFit PH PM

$XAIRMed

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last ye

$XAIRMed

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement fo

$XAIRMed

Beyond Air, Inc. Q1 2027 Earnings Call Summary

Beyond Air, Inc. reported Q1 2027 revenue of $1.8 million, citing long hospital contracting cycles. Management said its sales pipeline doubled and secured a national GPO agreement. It reaffirmed 2026 revenue guidance of $8 million and projected 2027 revenue of $16-$18 million, tied to Gen II LungFit PH FDA timing. A $30 million financing supports Gen II launch.

$XAIRMed

Beyond Air (XAIR) Q1 2027 Earnings Call Transcript

Beyond Air (XAIR) held a Q1 2027 earnings call. It reported Q ended June 30, 2026 revenue of $1.8 million, flat vs the prior quarter, with gross margin rising to 13% from 9%. The company reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million, pending FDA approval for its Gen II LungFit PH system. It also entered a national GPO deal and announced financing up to $30 million.